Clinical Trial Update: The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating tolvaptan for tricuspid regurgitation and right-sided heart failure after left heart valve replacement has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Right-sided Heart Failure
• Tricuspid Regurgitation

Drugs mentioned

• Samsca (tolvaptan)

Snippet

Sponsor: Shanghai Chest Hospital | Conditions: Tricuspid Regurgitation, Right Heart Failure | Phase 4 | Status: COMPLETED